3-hydroxymethyl-2,2,5,5-tetramethylpyrroline-n-oxyl has been researched along with haloperidol in 1 studies
Studies (3-hydroxymethyl-2,2,5,5-tetramethylpyrroline-n-oxyl) | Trials (3-hydroxymethyl-2,2,5,5-tetramethylpyrroline-n-oxyl) | Recent Studies (post-2010) (3-hydroxymethyl-2,2,5,5-tetramethylpyrroline-n-oxyl) | Studies (haloperidol) | Trials (haloperidol) | Recent Studies (post-2010) (haloperidol) |
---|---|---|---|---|---|
10 | 0 | 2 | 20,330 | 1,753 | 3,294 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Ishida, S; Ogata, T; Yokoyama, H | 1 |
1 other study(ies) available for 3-hydroxymethyl-2,2,5,5-tetramethylpyrroline-n-oxyl and haloperidol
Article | Year |
---|---|
In vivo temporal EPR study using a region-selected intensity determination method to estimate cerebral reducing ability in rats treated with olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Blood-Brain Barrier; Cerebral Cortex; Corpus Striatum; Cyclic N-Oxides; Electron Spin Resonance Spectroscopy; Half-Life; Haloperidol; Image Processing, Computer-Assisted; Imaging, Three-Dimensional; Magnetic Resonance Spectroscopy; Male; Models, Animal; Olanzapine; Oxidation-Reduction; Prefrontal Cortex; Pyrrolidines; Rats; Rats, Wistar | 2010 |